Bloomberg quoted people familiar with the matter as reporting that Mindray Medical (300760.SZ), a medical equipment manufacturer from Nanshan District, Shenzhen, has selected Huatai Securities and JPMorgan Chase to handle the preparations for the Hong Kong IPO, and may introduce more investment banks to participate later.
Earlier market news said that Mindray Healthcare aims to launch a secondary listing in Hong Kong and raise at least US$1 billion.
Asthe world's leading supplier of medical devices and solutions, Mindray Medical has the most complete product line in the domestic industry. Its monitors, anaesthesia machines, ventilators, defibrillators, blood cells, ultrasound and other products have a global market share. The rate ranks among the top three.Through cooperation with medical institutions, the company has built an open and growing"Sanrui"ecosystem and achieved the initial integration of"equipment+IT+AI". The company's medical ecosystem continuesto deepen clinical practice, focusing on critical departments.In 2024, the Qiyuan Critical Disease Model was launched.It is expected that it will be applied to other departments such as emergency department, anesthesiology department, imaging department, and laboratory department in the future, and digital intelligence will be fully rolled out in auxiliary diagnosis and treatment, report generation and review, clinical case and knowledge retrieval, teaching and scientific research and other fields.
Mindray Medical(300760.SZ)was listed on the A-share marketon October 16, 2018,with a current market value of approximatelyRMB 290.5 billion.
Copyright statement:All original articles by Ryanben Capital must be reprinted with authorization, and the source, author, and WeChat ID must be indicated at the beginning/end of the article, otherwise Ryanben will hold them for legal responsibility. Some articles were not able to get in touch with the original author or the public account platform when pushing.If copyright issues are involved, please contact us for the original author.
For more information on overseas IPOs such as Hong Kong listings and U.S. listings, please visit: www.ryanbencapital.com
Mindray Medical is rumored to be a secondary listing in Hong Kong with a market value of more than 270 billion yuan| A-share companies listed in Hong Kong,
CICC, CITIC, and Huatai continue to rank among the top three "Hong Kong IPO sponsors"(ranking of Hong Kong listed intermediaries in the past two years: as of August 2025)
Jingtian Gongcheng, Tongshang, Kindu, Junhe, Zhonglun, Tianyuan, ranked among the top six "Hong Kong IPO China Lawyers"(ranking of Hong Kong listed intermediaries in the past two years: as of August 2025)
Ernst & Young, PricewaterhouseCoopers, and KPMG, ranked among the top three "Hong Kong IPO Auditors"(ranking of Hong Kong listed intermediaries in the past two years: as of August 2025)
Gao Weishen, Meimais, Puheng, Davey, and Shengde, ranked among the top five" IPO Hong Kong lawyers"(ranking of Hong Kong listed intermediaries in the past two years: as of August 2025)
59 companies listed in the first eight months, raising 134.5 billion yuan, an increase of 5.8 times, 277 cases were submitted| Hong Kong IPO market in 2025
原文链接：https://027life.cn/223.html